VativoRx to be featured on PBS stations in US

Across hospitals, health systems, outpatient facilities, and infusion centers, operational change is constant. Mergers, site expansions, vendor shifts, and staffing changes are now part of the normal operating environment.

What’s less visible is how these transitions can quietly introduce rebate risk—not through noncompliance or system failure, but through gradual misalignment.

Rebate programs rarely collapse overnight. More often, they drift.

Specialty drug spend continues to rise across hospitals, outpatient facilities, and infusion centers. While the financial pressure is well known, the way it manifests is often misunderstood.

As healthcare organizations turn their attention toward 2026 planning, many finance and revenue leaders are finalizing budgets, forecasts, and growth priorities. Yet one critical step is often overlooked at year-end:

As specialty drug spending accelerates and reimbursement pressures mount, hospitals and outpatient systems are increasingly rethinking how they manage financial visibility across the medical benefit. The latest 2025 PBM Customer Satisfaction Report from Pharmaceutical Strategies Group (PSG) offers important context for this shift.